NCT00570232View on ClinicalTrials.gov

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Head and Neck Cancer
Interventions
DRUG

Erlotinib

150 mg per day by mouth for 12 months

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

University of Alabama at Birmingham

OTHER